New obesity drug aims to boost metabolism and burn fat faster

NCT ID NCT06745284

Ongoing Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether survodutide, a new weekly injection, helps people with obesity burn more energy and fat compared to the existing drug semaglutide (Wegovy). 64 adults aged 18-65 with a BMI between 30 and 45 will be randomly assigned to one of the two drugs. Researchers will measure changes in metabolism and fat burning using a special room that tracks oxygen and carbon dioxide. The study lasts 8-10 months and is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Survodutide (also known as BI 456906) and semaglutide (also known as Wegovy)
What this could lead to: If it works, survodutide could offer a new option for weight loss that may be more effective at boosting metabolism and fat burning than current treatments.
What could go wrong: This is a small, early-phase study with only 64 participants, so results may not apply to everyone. The drug may cause side effects or fail to show a clear benefit over semaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

AdventHealth - Translation Research Institute

Orlando, Florida, 32804, United States
Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.